Just as a reminder, Medicare’s negotiated price for Stelara is $4,695 per 30-day supply. That is a 66% discount from the wholesale acquisition cost (WAC). The current discount for biosimilar ustekinumab is 85% to 92%, yielding prices of $1500–$2,300 per month. Johnson and Johnson, Stelara’s manufacturer, wishes its lowest net price was $4,700 per month! … Continue reading Biosimilar Savings for Stelara Make Medicare’s Negotiated Price Seem Like a Bad Deal; Don’t Expect Biosimilar Savings on Enbrel